Concepedia

Chandrika Jeyamohan

CJ

Statistics

Publications

5

Citations

434

H-Index

5

Active since

2010

Affiliations

Rutgers, The State University of New Jersey(Current)

Rutgers Cancer Institute

Bristol-Myers Squibb (United States)

Johnson University

Chandrika Jeyamohan is an author at Rutgers, The State University of New Jersey specializing in medicine, oncology, and molecular oncology.

Publications per year

2010–2024

5

Publications

5

Targeting tumor metabolism with 2‐deoxyglucose in patients with castrate‐resistant prostate cancer and advanced malignancies

Mark N. Stein, Hongxia Lin, Chandrika Jeyamohan et al. · The Prostate · 2010 · 293 citations · Full text

, , +17

<i>BRAF</i> Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in <i>BRAF</i>V600E Mutant Melanoma

Atul Kulkarni, Husam Al-hraishawi, Srilatha Simhadri et al. · Clinical Cancer Research · 2017 · 61 citations

, , +17

A Phase II Study of AT-101 to Overcome Bcl-2–Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer

Mark N. Stein, Maha Hussain, Walter M. Stadler et al. · Clinical Genitourinary Cancer · 2015 · 52 citations

, , +17

A phase II, randomized study of nivolumab (NIVO), NIVO plus linrodostat mesylate, or NIVO plus intravesical bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, nonmuscle invasive bladder cancer (NMIBC): CheckMate 9UT.

Noah M. Hahn, Sam S. Chang, Maxwell V. Meng et al. · Journal of Clinical Oncology · 2020 · 14 citations

, , +6

Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies

Jason J. Luke, Karen A. Gelmon, Lillian L. Siu et al. · Clinical Cancer Research · 2024 · 14 citations

, , +17

1–5 of 5